Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clinical Development Setbacks, Pricing Pressures Hit Roche

Executive Summary

Recent setbacks for two of its most important pipeline projects, as well as a tougher pricing environment in key Western countries, will take a toll on Roche in 2010 and beyond, company executives told analysts during a half-year earnings call on July 22

You may also be interested in...



Roche Announces Internal Review Likely To Result In Staff, Program Cuts

Swiss pharma cites U.S. and EU health care spending constraints and regulatory setbacks as reasons for plan.

Roche's T-DM1 Early Filing Strategy Backfires As FDA Refuses To File BLA

It hasn't been a swell summer for Roche, and now a bit of near-term pipeline news that could have put the company on a more positive trajectory has fallen flat. FDA refused to file Roche's BLA for breast cancer agent trastuzumab-DM1 (T-DM1), a conjugated version of Herceptin, for accelerated approval, the company announced Aug. 27

Roche's T-DM1 Early Filing Strategy Backfires As FDA Refuses To File BLA

It hasn't been a swell summer for Roche, and now a bit of near-term pipeline news that could have put the company on a more positive trajectory has fallen flat. FDA refused to file Roche's BLA for breast cancer agent trastuzumab-DM1 (T-DM1), a conjugated version of Herceptin, for accelerated approval, the company announced Aug. 27

Related Content

Topics

UsernamePublicRestriction

Register

PS052453

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel